शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

IOLCPBSEIOL CHEM AND PHARMA LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 30 Oct, 2026 · 18:02 IST

Q2 FY27 profit doubles to Rs 65 crore as revenue rises 40%

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDFExplain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.5%Reaction day
₹178.99
prior close
₹179.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-1.0% vs market
Pharmaceuticals peers, median of 174sector+0.2%+0.3% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.2
10m
-1.3
15m
-0.6
30m
-0.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.5+1.4-1.0+0.2+0.3
Next day
-3.2+1.7-4.9+0.6-3.9
2d
+3.3+3.9-0.6+1.6+1.7
3d
+5.3+5.1+0.2+2.3+3.0
4d
+3.0pendingpending+2.2+0.8
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and half-year results for the quarter ended 30 Sep 2026; statutory auditors gave an unmodified review. Q2 revenue rose 40% to Rs 795.03 crore from Rs 567.53 crore, and profit after tax more than doubled to Rs 65.03 crore from Rs 30.00 crore. Half-year revenue was Rs 1,551.29 crore and profit Rs 129.51 crore, versus Rs 1,119.22 crore and Rs 63.96 crore. EPS was Rs 2.21. Pharma led growth.

Likely market impact

Strong revenue and profit growth with wider margins supports the stock, but operating cash flow of Rs 8.32 crore was thin.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹795.0 Cr₹567.5 Cr+40.1%
Operating profit₹81.78 Cr₹33.61 Cr+143.3%
Profit after tax₹65.07 Cr₹29.97 Cr+117.1%
EBITDA margin13.8%10.1%+3.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.